AstraZeneca Boosts China Presence with $136mln Investment and New R&D Center

AstraZeneca, a British pharmaceutical company, is deepening its partnership with China, driven by the country's efforts to expand high-standard opening up and its growing innovation ecosystem. The company has invested an additional $136m in its manufacturing base in Qingdao and plans to establish a global strategic R&D center in Beijing. AstraZeneca sees China as a strategic hub for R&D and manufacturing, leveraging the country's innovation and science capability to deepen its presence in the market.